# Task C1: A Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1 Study of SARS-CoV-2 Therapeutics

> **NIH NIH N01** · DYNPORT VACCINE COMPANY, LLC · 2024 · $245,549

## Abstract

The Early Phase Clinical Trial Units provide a vehicle for investigation of new agents in the treatment and prevention of infectious diseases and can carry out all aspects of interventional clinical trial implementation.

## Key facts

- **NIH application ID:** 11202302
- **Project number:** 75N93022D00016-P00002-759302300001-2
- **Recipient organization:** DYNPORT VACCINE COMPANY, LLC
- **Principal Investigator:** CASEY LONG
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $245,549
- **Award type:** —
- **Project period:** 2023-05-15 → 2024-10-07

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11202302

## Citation

> US National Institutes of Health, RePORTER application 11202302, Task C1: A Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1 Study of SARS-CoV-2 Therapeutics (75N93022D00016-P00002-759302300001-2). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/11202302. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*